Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies
- 1 April 2003
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 4 (4), 215-223
- https://doi.org/10.1016/s1470-2045(03)01044-1
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- CancerVax, An Allogeneic Tumor Cell Vaccine, Induces Specific Humoral and Cellular Immune Responses in Advanced Colon CancerAnnals of Surgical Oncology, 2001
- Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Renal Cell CarcinomaJapanese Journal of Cancer Research, 1999
- Primary proliferative T cell response to wild‐type p53 protein in patients with breast cancerEuropean Journal of Immunology, 1995
- A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3European Journal of Immunology, 1994
- Cytotoxic T Cells Isolated from Ovarian Malignant Ascites Recognize a Peptide Derived from the HER-2/neu Proto-oncogeneCellular Immunology, 1993
- CD4+ T Cell Clones Isolated from Human Renal Cell Carcinoma Possess the Functional Characteristics of Th2 Helper CellsCellular Immunology, 1993
- Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral ProteinScience, 1993
- A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.The Journal of Experimental Medicine, 1992
- Autologous Tumor-Specific Cytotoxicity of Tumor-Infiltrating Lymphocytes Derived from Human Renal Cell CarcinomaJournal of Immunotherapy, 1991
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988